
[Chart courtesy of MarketWatch.com]
- Moving the markets
Optimists got a slap in the face, as reports of the greatly hyped experimental coronavirus drug Remdesivir, by Gilead, delivered disappointing results in clinical trials. That was enough of a downer for the markets to buckle, and the early gains were slowly wiped out, despite attempts to revive the bullish theme.
Looking at the chart above, this must have been one of the slowest days in recent weeks, with the major indexes ending the day just about unchanged.
Not helping the mood were reports from Europe, as their much-anticipated summit turned out to be a total flop with no agreement on a recovery package reached, as four “frugal” EU countries opposed any grants.
Then we learned that the housing market is not doing well, although that comes as no surprise, as New Home Sales crashed by 15.4% MoM, the biggest drop since July 2013, as ZeroHedge noted. This was also the biggest decline for March—ever!
Another 4.427 million Americans filed for first time unemployment in the last week bringing the four-week claims total to 26.5 million jobs lost. If you look at the “initial” and “continuing” claims, as per Bloomberg, it shows the highest level of continuing claims ever.
That means, we have now exceeded the jobs created in the past 10 years by the number job losses in the last 5 weeks. Stunning! Yet, current market levels in no way reflect those facts but, at least for today, equities did not rally into the close.
Summing up the day using the Good, Bad and Ugly analogy was Zero Hedge:
- The Good – Stocks are up (all it took was a few trillion dollars)? Oil is up (all it took was threats of war)?
- The Bad – COVID cases are up, COVID deaths are up (and Gilead’s drug is a dud)…
- The Ugly – Over 26 million Americans have now filed for unemployment benefits in the last 5 weeks.
A three-way-standoff between ugly real economic data, ongoing global lockdowns, and the Fed’s “whatever it takes” asset lift-a-thon…
What’s next? Will more bad news be good news again?
Read More



